Kinomica is a spin-out founded at the Barts Cancer Institute using phosphoproteomics to guide more precise cancer treatment decisions.
Kinomica is developing new diagnostic tools to help match patients with the treatments most likely to work for them. Its platform, KScan, uses phosphoproteomics — measuring protein activity and signalling within cells — to assess how tumours respond to drugs and identify the most effective therapeutic options.
Founded by Professor Pedro Cutillas, David Britton and Professor John Gribben, Kinomica builds on more than 15 years of research at Barts Cancer Institute, Queen Mary University of London. The company translates advances in proteomic science into clinically relevant tools, complementing genomic approaches by capturing how cancer cells are actively behaving, rather than relying on static genetic information alone.
KScan enables researchers and clinicians to monitor drug response, understand mechanisms of resistance and support patient stratification in clinical trials. This makes it valuable not only for guiding treatment decisions, but also for improving how new therapies are developed and tested. The technology has attracted investment from Innovate UK and leading life sciences investors, and the company is working with pharmaceutical partners to apply its platform in drug development.
By helping to match patients with the most appropriate treatments, this approach could reduce ineffective therapies and support more personalised cancer care.